418 related articles for article (PubMed ID: 10052975)
21. Differentiation between partial agonists and neutral 5-HT1B antagonists by chemical modulation of 3-[3-(N,N-dimethylamino)propyl]-4-hydroxy- N-[4-(pyridin-4-yl)phenyl]benzamide (GR-55562).
Lamothe M; Pauwels PJ; Belliard K; Schambel P; Halazy S
J Med Chem; 1997 Oct; 40(22):3542-50. PubMed ID: 9357521
[TBL] [Abstract][Full Text] [Related]
22. How efficacious are 5-HT1B/D receptor ligands: an answer from GTP gamma S binding studies with stably transfected C6-glial cell lines.
Pauwels PJ; Tardif S; Palmier C; Wurch T; Colpaert FC
Neuropharmacology; 1997; 36(4-5):499-512. PubMed ID: 9225275
[TBL] [Abstract][Full Text] [Related]
23. Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors.
Newman-Tancredi A; Cussac D; Audinot V; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):447-53. PubMed ID: 10431754
[TBL] [Abstract][Full Text] [Related]
24. Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries.
Hamel E; Fan E; Linville D; Ting V; Villemure JG; Chia LS
Mol Pharmacol; 1993 Aug; 44(2):242-6. PubMed ID: 8394988
[TBL] [Abstract][Full Text] [Related]
25. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Heightman TD; Gaster LM; Pardoe SL; Pilleux JP; Hadley MS; Middlemiss DN; Price GW; Roberts C; Scott CM; Watson JM; Gordon LJ; Holland VA; Powles J; Riley GJ; Stean TO; Trail BK; Upton N; Austin NE; Ayrton AD; Coleman T; Cutler L
Bioorg Med Chem Lett; 2005 Oct; 15(19):4370-4. PubMed ID: 16039851
[TBL] [Abstract][Full Text] [Related]
26. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
[TBL] [Abstract][Full Text] [Related]
27. 5-HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs.
Villalón CM; Centurión D; Sánchez-López A; De Vries P; Saxena P
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1057-67. PubMed ID: 11216445
[TBL] [Abstract][Full Text] [Related]
28. 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
Russell MG; Matassa VG; Pengilley RR; van Niel MB; Sohal B; Watt AP; Hitzel L; Beer MS; Stanton JA; Broughton HB; Castro JL
J Med Chem; 1999 Dec; 42(24):4981-5001. PubMed ID: 10585208
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
Medina RA; Sallander J; Benhamú B; Porras E; Campillo M; Pardo L; López-Rodríguez ML
J Med Chem; 2009 Apr; 52(8):2384-92. PubMed ID: 19326916
[TBL] [Abstract][Full Text] [Related]
30. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
31. Imidazoline-modified benzylimidazolines as h5-HT(1D/1B) serotonergic ligands.
Prisinzano T; Law H; Dukat M; Slassi A; MaClean N; Demchyshyn L; Glennon RA
Bioorg Med Chem; 2001 Mar; 9(3):613-9. PubMed ID: 11310595
[TBL] [Abstract][Full Text] [Related]
32. SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'methyl-4'-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist.
Scott C; Langmead CJ; Clarke KL; Wyman P; Smith PW; Starr KR; Dawson LA; Price GW; Hagan JJ; Watson J
Neuropharmacology; 2006 Jun; 50(8):984-90. PubMed ID: 16546225
[TBL] [Abstract][Full Text] [Related]
33. A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.
May JA; Chen HH; Rusinko A; Lynch VM; Sharif NA; McLaughlin MA
J Med Chem; 2003 Sep; 46(19):4188-95. PubMed ID: 12954071
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological diversity between native human 5-HT1B and 5-HT1D receptors sited on different neurons and involved in different functions.
Marcoli M; Maura G; Munari C; Ruelle A; Raiteri M
Br J Pharmacol; 1999 Feb; 126(3):607-12. PubMed ID: 10188970
[TBL] [Abstract][Full Text] [Related]
35. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
[TBL] [Abstract][Full Text] [Related]
36. Cycloalkanecarboxylic esters derived from lysergol, dihydrolysergol-I, and elymoclavine as partial agonists and antagonists at rat 5-HT2A receptors: pharmacological evidence that the indolo[4,3-fg]quinoline system of the ergolines is responsible for high 5-HT2A receptor affinity.
Pertz HH; Milhahn H; Eich E
J Med Chem; 1999 Feb; 42(4):659-68. PubMed ID: 10052973
[TBL] [Abstract][Full Text] [Related]
37. Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist.
Doménech T; Beleta J; Palacios JM
Naunyn Schmiedebergs Arch Pharmacol; 1997 Sep; 356(3):328-34. PubMed ID: 9303569
[TBL] [Abstract][Full Text] [Related]
38. Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
Jandu KS; Barrett V; Brockwell M; Cambridge D; Farrant DR; Foster C; Giles H; Glen RC; Hill AP; Hobbs H; Honey A; Martin GR; Salmon J; Smith D; Woollard P; Selwood DL
J Med Chem; 2001 Mar; 44(5):681-93. PubMed ID: 11262079
[TBL] [Abstract][Full Text] [Related]
39. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
Leopoldo M; Berardi F; Colabufo NA; Contino M; Lacivita E; Niso M; Perrone R; Tortorella V
J Med Chem; 2004 Dec; 47(26):6616-24. PubMed ID: 15588097
[TBL] [Abstract][Full Text] [Related]
40. A novel series of 2,5-substituted tryptamine derivatives as vascular 5HT1B/1D receptor antagonists.
Moloney GP; Robertson AD; Martin GR; MacLennan S; Mathews N; Dodsworth S; Sang PY; Knight C; Glen R
J Med Chem; 1997 Jul; 40(15):2347-62. PubMed ID: 9240350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
